The results showed that overexpression of LINC01852 significantly increased, whereas silencing LINC01852 expression strikingly reduced the sensitivity of CRC cells to these chemotherapeutic agents (Fig. 3A and B). This evidence concerns the gene LINC01852 and colorectal carcinoma.